Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis

Yu, Ying‐Hui; Cheng, Qinzhen; Ji, Xiaoyuan; Chen, Hongzhong; Zeng, Wenfeng; Zeng, Xiaowei; Zhao, Yanli; Mei, Lin

doi:10.1126/sciadv.add3599

Cited by 64 publications

(30 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, bio-nanoparticles have received increasing attention due to their excellent biological activity. Among the various membrane biomaterials, PLTMs, given their multitude of interactions with other cell types, have attracted much attention due to their significant tumour targeting and immune escape potential (Wang et al 2023;Yu et al 2022). In this study, we aimed to leverage these unique abilities to design a pH/ glutathione (GSH) dual-responsive bio-nanogel delivery system (Xu et al 2021).…”

Section: Preparation and Characterization Of Dox@pngsmentioning

confidence: 99%

Functional targeted therapy for glioma based on platelet membrane-coated nanogels

Shen

et al. 2023

Cancer Nano

View full text Add to dashboard Cite

Glioma treatment remains a challenge owing to unsatisfactory targeted chemotherapy, where the blood–brain barrier (BBB) hinders the efficient uptake of therapeutics into the brain. Vasculogenic mimicry (VM) formed by invasive glioma cells negatively affects the treatment of glioma. Herein, we developed a targeted biomimetic drug delivery system comprising a doxorubicin-loaded platelet membrane-coated nanogel (DOX@PNGs). The nanogels provide great redox/pH dual responsiveness, while the platelet membrane (PLTM) promotes stability and circulation time. In vitro cellular uptake and in vivo imaging experiments demonstrated that the DOX@PNGs delivery system could penetrate the BBB, target gliomas, and destruct VM. DOX@PNGs increased drug penetration and prolonged mouse survival time during the treatment of orthotopic gliomas. These results indicate this biomimetic drug delivery system to be promising for glioma treatment and may be clinically translated in the future.

show abstract

Section: Preparation and Characterization Of Dox@pngsmentioning

confidence: 99%

Functional targeted therapy for glioma based on platelet membrane-coated nanogels

Shen

et al. 2023

Cancer Nano

View full text Add to dashboard Cite

show abstract

“…In addition, some of the infiltration immune cells in the tumor are mostly transformed into tumor-promoting immunosuppressive cells, which further restricted the therapeutic efficacy [ 2 , 3 ]. Previous studies have been proved that the tumor cells undergoing immunogenic cell death (ICD) release tumor-associated antigens to activate anti-tumor immune effect and recruit CTLs [ 4 – 6 ]. Some traditional therapies, like radiation therapy (RT), chemotherapy (CT) and photodynamic therapy (PDT) are effective ways to induce ICD, and they were reported to achieve better efficacy when combined with ICB [ 7 – 9 ].…”

Section: Introductionmentioning

confidence: 99%

Copper-induced injectable hydrogel with nitric oxide for enhanced immunotherapy by amplifying immunogenic cell death and regulating cancer associated fibroblasts

et al. 2023

View full text Add to dashboard Cite

Background Immunogenic cell death (ICD) induced by different cancer treatments has been widely evaluated to recruit immune cells and trigger the specific antitumor immunity. However, cancer associated fibroblasts (CAFs) can hinder the invasion of immune cells and polarize the recruited monocytes to M2-type macrophages, which greatly restrict the efficacy of immunotherapy (IT). Methods In this study, an injectable hydrogel induced by copper (Cu) has been designed to contain antibody of PD-L1 and nitric oxide (NO) donor. The therapeutic efficacy of hydrogel was studied in 4T1 cells and CAFs in vitro and 4T1 tumor-bearing mice in vivo. The immune effects on cytotoxic T lymphocytes, dendritic cells (DCs) and macrophages were analyzed by flow cytometry. Enzyme-linked immunosorbent assay, immunofluorescence and transcriptome analyses were also performed to evaluate the underlying mechanism. Results Due to the absorbance of Cu with the near-infrared laser irradiation, the injectable hydrogel exhibits persistent photothermal effect to kill cancer cells. In addition, the Cu of hydrogel shows the Fenton-like reaction to produce reactive oxygen species as chemodynamic therapy, thereby enhancing cancer treatment and amplifying ICD. More interestingly, we have found that the released NO can significantly increase depletion of CAFs and reduce the proportion of M2-type macrophages in vitro. Furthermore, due to the amplify of ICD, injectable hydrogel can effectively increase the infiltration of immune cells and reverse the immunosuppressive tumor microenvironment (TME) by regulating CAFs to enhance the therapeutic efficacy of anti-PD-L1 in vivo. Conclusions The ion induced self-assembled hydrogel with NO could enhance immunotherapy via amplifying ICD and regulating CAFs. It provides a novel strategy to provoke a robust antitumor immune response for clinical cancer immunotherapy. Graphical Abstract

show abstract

“…[ 50 ] Therefore, mono‐therapy targeting either biochemical cues or physical cues is not enough to cope with the complex TME of breast cancer. Although combination therapies based on two or more types of therapy (e.g., photothermal combined immunotherapy, [ 51 ] photothermal combined chemotherapy, [ 52 ] chemo‐immune combined therapy, [ 53 ] and chemo‐radio combined therapy [ 54 ] ) have been recently developed, mechanochemical combination therapy for breast cancer treatment remains largely unexplored.…”

Section: Introductionmentioning

confidence: 99%

Combination Therapy of Lox Inhibitor and Stimuli‐Responsive Drug for Mechanochemically Synergistic Breast Cancer Treatment

Zhu

Zhang

Gao

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Chemotherapy based on small molecule drugs, hormones, cycline kinase inhibitors, and monoclonal antibodies has been widely used for breast cancer treatment in the clinic but with limited efficacy, due to the poor specificity and tumor microenvironment (TME)‐caused diffusion barrier. Although monotherapies targeting biochemical cues or physical cues in the TME have been developed, none of them can cope with the complex TME, while mechanochemical combination therapy remains largely to be explored. Herein, a combination therapy strategy based on an extracellular matrix (ECM) modulator and TME‐responsive drug for the first attempt of mechanochemically synergistic treatment of breast cancer is developed. Specifically, based on overexpressed NAD(P)H quinone oxidoreductase 1 (NQO1) in breast cancer, a TME‐responsive drug (NQO1‐SN38) is designed and it is combined with the inhibitor (i.e., β‐Aminopropionitrile, BAPN) for Lysyl oxidases (Lox) that contributes to the tumor stiffness, for mechanochemical therapy. It is demonstrated that NQO1 can trigger the degradation of NQO1‐SN38 and release SN38, showing nearly twice tumor inhibition efficiency compared with SN38 treatment in vitro. Lox inhibition with BAPN significantly reduces collagen deposition and enhances drug penetration in tumor heterospheroids in vitro. It is further demonstrated that the mechanochemical therapy showed outstanding therapeutic efficacy in vivo, providing a promising approach for breast cancer therapy.

show abstract

Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis

Cited by 64 publications

References 48 publications

Functional targeted therapy for glioma based on platelet membrane-coated nanogels

Functional targeted therapy for glioma based on platelet membrane-coated nanogels

Copper-induced injectable hydrogel with nitric oxide for enhanced immunotherapy by amplifying immunogenic cell death and regulating cancer associated fibroblasts

Combination Therapy of Lox Inhibitor and Stimuli‐Responsive Drug for Mechanochemically Synergistic Breast Cancer Treatment

Contact Info

Product

Resources

About